Routine

Menopause & perimenopause — symptom management and HRT

Permanent cessation of menstruation from ovarian failure; perimenopausal vasomotor, urogenital and psychological symptoms. Covers HRT choice, risks/benefits and non-hormonal options (NICE NG23). DRAFT for clinician review. · Gynaecology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Menopause is the permanent cessation of menstruation (diagnosed retrospectively after 12 months of amenorrhoea), average age ~51; perimenopause is the preceding transition of fluctuating hormones and symptoms. Common symptoms: vasomotor (hot flushes, night sweats), sleep disturbance, mood/cognitive changes, genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms) and reduced bone density. Diagnosis is clinical in women over 45 with typical symptoms (no routine hormone testing needed); FSH may help under 45 or where uncertain. Hormone replacement therapy (HRT) is the most effective treatment for vasomotor and urogenital symptoms and protects bone; the regimen depends on whether the woman has a uterus (needs a progestogen for endometrial protection) and her menstrual status. Premature ovarian insufficiency (< 40 years) warrants HRT at least to the natural age of menopause.

Red flags

  • Postmenopausal bleeding or unscheduled/persistent bleeding on HRT — investigate for endometrial cancer
  • New focal neurology, severe headache, or chest pain/leg swelling on oral HRT (stroke/VTE)
  • Breast lump / strong breast cancer history (affects HRT suitability)
  • Premature ovarian insufficiency (< 40) — needs HRT and bone/cardiovascular protection
  • Severe low mood / suicidality in perimenopause
  • Severe osteoporosis / fragility fracture

Assessment

Differential diagnosis

  • Perimenopause / menopause (clinical)
  • Premature ovarian insufficiency (< 40 years)
  • Thyroid disease (hyper/hypothyroidism mimicking flushes/mood/menstrual change)
  • Pregnancy (amenorrhoea in perimenopause)
  • Anxiety/depression, other causes of mood/sleep disturbance
  • Other causes of flushing (carcinoid, phaeochromocytoma, medication, alcohol)
  • Abnormal uterine bleeding from endometrial pathology (investigate postmenopausal/irregular bleeding)

Investigations

  • Clinical diagnosis in women >= 45 with typical symptoms — routine FSH/hormone testing NOT required
  • FSH (raised) to support diagnosis if < 45 years, atypical, or for suspected premature ovarian insufficiency (two readings 4-6 weeks apart if < 40)
  • Thyroid function if symptoms overlap; consider other tests per differential
  • Investigate any postmenopausal bleeding or unscheduled bleeding on HRT (ultrasound +/- endometrial biopsy) to exclude endometrial cancer
  • Assess cardiovascular risk, VTE risk, breast and migraine history before HRT; blood pressure, BMI
  • Bone health / fracture risk assessment (FRAX, DEXA) where indicated, esp. early menopause

Management

  • Confirm menopause clinically; assess symptom burden and impact, and individual risk factors (VTE, breast cancer, cardiovascular, migraine)
  • Offer HRT as first-line for vasomotor symptoms unless contraindicated, after discussing benefits/risks (individualised, shared decision)
  • Choose regimen: with uterus -> oestrogen + progestogen (sequential if perimenopausal/still bleeding; continuous combined if postmenopausal >12 months) for endometrial protection; without uterus -> oestrogen alone
  • Prefer transdermal oestrogen (patch/gel) where VTE/cardiovascular risk, migraine, or patient preference — lower VTE and stroke risk than oral
  • Use micronised progesterone or levonorgestrel IUS for progestogen component (IUS also gives contraception); counsel that HRT is not contraceptive
  • Add vaginal (local) oestrogen for genitourinary symptoms — can be used alone or alongside systemic HRT, long-term, with minimal systemic absorption
  • Non-hormonal options if HRT declined/contraindicated: SSRIs/SNRIs or clonidine for flushes, CBT; vaginal moisturisers/lubricants; newer NK3-receptor antagonists (e.g. fezolinetant) where available
  • Premature ovarian insufficiency: offer HRT (or combined contraceptive) at least until the natural age of menopause (~51) for symptom and bone/cardiovascular protection
  • Review at 3 months then annually; reassess benefits/risks; no arbitrary upper time limit — individualise; manage bleeding and side effects

Drugs & doses

Transdermal 17-beta-estradiol patch (e.g. 25-100 micrograms/24 h twice weekly) or estradiol gel — preferred where VTE/stroke/migraine risk (lower VTE risk than oral) [verify local dose]
Oral estradiol 1-2 mg PO daily (alternative where transdermal not preferred)
Progestogen (if uterus present): micronised progesterone 100 mg PO at night (continuous) or 200 mg for 12 days/cycle (sequential); OR levonorgestrel IUS 52 mg (endometrial protection + contraception) [verify local]
Vaginal (local) oestrogen: estriol cream or estradiol 10 microgram pessary (daily 2 weeks then twice weekly) for genitourinary syndrome — long-term, minimal systemic absorption
Non-hormonal vasomotor: SSRI/SNRI e.g. venlafaxine 37.5-75 mg PO daily, or citalopram/escitalopram; clonidine as alternative [verify local]
Fezolinetant (NK3-receptor antagonist) for vasomotor symptoms where available/licensed — check LFTs [verify local]
Vaginal moisturisers/lubricants for dryness/dyspareunia (non-hormonal)
Testosterone (transdermal) can be added for low sexual desire unresponsive to HRT — specialist, off-label, monitor levels [verify local]

Disposition

Primary care / menopause clinic management for most. Refer to specialist menopause service for complex cases, premature ovarian insufficiency, treatment-resistant symptoms, or where HRT risk assessment is complex (e.g. prior VTE, breast cancer). Investigate postmenopausal bleeding via gynaecology. Review HRT at 3 months then annually. Bone health follow-up where indicated.

Complications & pitfalls

  • Osteoporosis and fragility fractures (oestrogen deficiency)
  • Genitourinary syndrome of menopause (recurrent UTI, dyspareunia)
  • Cardiovascular disease risk changes; reduced quality of life, mood disturbance
  • HRT-related: small increased breast cancer risk (combined, duration-dependent), VTE (oral > transdermal), stroke (oral), endometrial hyperplasia if unopposed oestrogen with a uterus
  • Premature ovarian insufficiency sequelae if untreated

Exam pearls

  • Diagnose menopause clinically in women over 45 — do not routinely check hormone levels.
  • HRT is the most effective treatment for vasomotor and urogenital symptoms and protects bone.
  • A woman with a uterus needs a progestogen with her oestrogen to protect the endometrium.
  • Transdermal oestrogen carries lower VTE/stroke risk than oral — prefer it where there is vascular/VTE/migraine risk.
  • Local vaginal oestrogen treats genitourinary symptoms safely long-term and can be combined with systemic HRT.
  • Always investigate postmenopausal or unscheduled bleeding to exclude endometrial cancer.
  • Treat premature ovarian insufficiency with HRT at least until the usual age of menopause; HRT is not a contraceptive.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.